Quralis Corp.

6 trials 1 recruiting Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

5 Completed trials

4 Countries active

0 Unique IMPs

100% Results reported

Phase I

Phase I (Other)

Phase I: 1 Phase I (Other): 5

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Amyotrophic lateral sclerosis 4 Epilepsy 1

All trials

6 total

A Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants Recruiting

2025-524310-28-00 Phase I (Other) 1 country
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-20… Ended

2022-500758-41-00 Phase I 4 countries
A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy Participants Ended

2024-518833-27-00 Phase I (Other) 1 country
A Randomized, Placebo-Controlled, Double-Blind, Single Dose, Phase 1 Study to Explore the PK/PD Relationship of QRL-101 in People Living Wit… Ended

2024-515021-29-00 Phase I (Other) 1 country
A study on the effects of a new drug on the sensitivity of the nerves in healthy volunteers Ended

2024-515390-99-00 Phase I (Other) 1 country
A randomized, placebo-controlled, double blind, multiple ascending dose, phase 1 study to evaluate the safety, tolerability, and pharmacokin… Ended

2024-513127-16-00 Phase I (Other) 1 country

Showing 1–6 of 6 trials

← All sponsors A–Z